Literature DB >> 204442

Uptake by bone of pyrophosphate, diphosphonates and their technetium derivatives.

S Bisaz, A Jung, H Fleisch.   

Abstract

1. The uptake of inorganic pyrophosphate (PPi) from blood to bone was investigated in the rat in vivo. 2. PPi is taken up by the bone, where it appears both as PPi and as inorganic orthophosphate (Pi). The latter is due at least partly to local hydrolysis. 3. The fraction of injected PPi taken up by bone, measured as total PPi, was in the same range as that of technetium-tin-PPi, diphosphonates, technetium-tin-ethane-1-hydroxy-1,1-diphosphonate and Pi, but lower than that of calcium. 4. The plasma half-life of PPi is in the same order of magnitude as that of technetium-tin-PPi, diphosphonates, technetium-tin-ethane-1-hydroxy-1,1-diphosphonate, Pi and calcium. 5. PPi, diphosphonates and their technetium complexes are only partly ultrafiltrable in plasma. 6. It appears that the technetium complexes behave in a similar fashion to free PPi or diphosphonate.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 204442     DOI: 10.1042/cs0540265

Source DB:  PubMed          Journal:  Clin Sci Mol Med        ISSN: 0301-0538


  8 in total

Review 1.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 2.  Strategies for management of prostate cancer-related bone pain.

Authors:  R C Pelger; V Soerdjbalie-Maikoe; N A Hamdy
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  Relationship between physicochemical and osteotropic properties of bisphosphonic derivatives: rational design for osteotropic drug delivery system (ODDS).

Authors:  H Hirabayashi; T Sawamoto; J Fujisaki; Y Tokunaga; S Kimura; T Hata
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

4.  Kinetics of 99mtechnetium-tin-methylene-diphosphonate in normal subjects and pathological conditions: a simple index of bone metabolism.

Authors:  A Caniggia; A Vattimo
Journal:  Calcif Tissue Int       Date:  1980       Impact factor: 4.333

Review 5.  Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  A Fitton; D McTavish
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

Review 6.  Bisphosphonates and the treatment of bone disease in the elderly.

Authors:  A Johansen; M Stone; F Rawlinson
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

Review 7.  Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents.

Authors:  Hideki Hirabayashi; Jiro Fujisaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats.

Authors:  Hisato Hikita; Ken Miyazawa; Masako Tabuchi; Masakazu Kimura; Shigemi Goto
Journal:  J Bone Miner Metab       Date:  2009-05-13       Impact factor: 2.626

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.